Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Clinical genetic evidence for TNNI3 (HGNC:11947) involvement in dilated cardiomyopathy (MONDO:0005021) remains limited. Six unrelated probands have been reported: a de novo heterozygous missense variant c.544G>A (p.Glu182Lys) in a neonatal case (PMID:38089682), a consanguineous family with three affected infants homozygous for a frameshift c.204del (p.Arg69AlafsTer8) (PMID:38924380), one proband in a 312-case DCM resequencing study (PMID:20215591), and one in a 105-patient screening cohort (PMID:21846512). Variants include two missense and one protein-truncating allele, with inheritance patterns consistent with both autosomal dominant (de novo) and autosomal recessive (homozygous) mechanisms. No additional segregation beyond the index cases has been documented.
Functional studies directly interrogating TNNI3 variants in DCM are sparse. Mechanistic insights derive largely from sarcomeric biophysics showing that troponin I mutations perturb thin filament regulation and diastolic function, implying a pathogenic mechanism of impaired relaxation via altered calcium sensitivity. Overall, the aggregate evidence supports a Limited ClinGen clinical validity classification, with preliminary functional concordance but insufficient segregation or cohort size to upgrade. Key take-home: TNNI3 variants are emerging contributors to DCM etiology, warranting targeted genetic screening in infantile and familial cases.
Gene–Disease AssociationLimitedSix probands across five families, including de novo and consanguineous cases; no extended segregation Genetic EvidenceLimitedSix independent cases with rare TNNI3 variants; below ClinGen threshold for Moderate Functional EvidenceLimitedIn vitro and biophysical assays imply altered Ca²⁺ sensitivity but no DCM-specific rescue or animal models |